Non-transgenic Rat Model for Alzheimer's Disease via Heavy Metal Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transgenic animal models for Alzheimer's disease are time-consuming, laborious, and ethically limited, with difficulties in replicating human brain anatomy, and existing non-transgenic models fail to induce early AD symptoms effectively, lacking vascular pathology representation.
Innovation Solution
A non-transgenic Wistar rat model is developed by exposing rats to a mixture of arsenic, cadmium, and lead at specific doses and times, inducing over-expression of amyloid beta peptides and associated proteins, mimicking early Alzheimer's disease pathology, including vascular damage and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic animal models are used to study Alzheimer's disease, then the model can replicate human brain anatomy and AD pathology, but the production process becomes time-consuming, laborious, and ethically limited
Solution Approach 1:
The patent uses non-transgenic Wistar rats that are orally exposed to heavy metal mixture, creating a copy of AD pathology without requiring transgenic modification. This copying approach replicates the key features of AD (Aβ plaques, neurofibrillary tangles, cognitive deficits) through environmental exposure rather than genetic engineering, thereby avoiding the time-consuming and ethically problematic transgenic production process while maintaining pathological relevance
Solution Approach 2:
The patent changes the exposure parameters by administering heavy metals (arsenic, cadmium, lead) at specific doses and time points to non-transgenic rats. This parameter-based approach induces AD-like pathology through controlled environmental exposure, achieving reliable disease modeling without the temporal and ethical constraints of transgenic animal production
2Loss of time
If non-transgenic models are used to avoid transgenic limitations, then the model production becomes faster and more ethical, but early AD symptoms and vascular pathology are not effectively induced
Solution Approach 1:
The patent employs a composite heavy metal mixture containing arsenic, cadmium, and lead in specific proportions. This composite exposure regime synergistically induces early AD symptoms and vascular pathology in non-transgenic rats, overcoming the limitation of simple non-transgenic models by using a combined environmental stressor approach that reliably replicates multiple aspects of early AD pathology including cognitive deficits and vascular damage
Solution Approach 2:
The patent applies preliminary exposure to heavy metal mixture during specific developmental periods (including gestation and early postnatal stages) to non-transgenic rats. This preliminary action during critical windows of brain development effectively induces early AD symptoms and vascular pathology, demonstrating that timed environmental exposure can achieve reliable disease modeling without transgenic modification
3Reliability
If Aβ peptide is infused into the brain to induce plaque deposition, then plaque formation is achieved, but cerebral layer thinning occurs due to chronic cannula implantation
Solution Approach 1:
The patent extracts the plaque induction mechanism from direct Aβ peptide infusion and replaces it with systemic heavy metal exposure. By taking out the need for chronic cannula implantation and substituting it with oral or intraperitoneal heavy metal administration, the model achieves reliable Aβ plaque deposition and neurofibrillary tangle formation without the harmful side effect of cerebral layer thinning associated with chronic surgical access
Solution Approach 2:
The patent introduces heavy metal mixture (arsenic, cadmium, lead) as an intermediary substance that mediates Aβ production and plaque formation indirectly. Rather than directly infusing Aβ peptide into the brain, the heavy metals serve as intermediaries that upregulate APP processing and Aβ generation through systemic exposure, thereby achieving plaque deposition without the mechanical trauma of chronic cannula implantation
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
The invention features a non-transgenic rat model for early AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity in rat cortex and hippocampus. This model can serve as a tool for (a) AD-directed drug screening, and (b) determining mechanism of AD pathogenicity. It features induction of the A?-mediated apoptosis and induction of inflammation in rodent brain. The invention features novel astrocyte and neuronal cellular models for AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity. This model can serve as a tool for (a) AD-directed drug screening in astrocytes and neurons, and (b) determining mechanism of AD pathogenicity in cells. It features induction of the A?-mediated apoptosis and induction of inflammation in astrocytes and neurons.